Velidakis, N.; Stachteas, P.; Gkougkoudi, E.; Papadopoulos, C.; Kadoglou, N.P.E.
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review. Pharmaceuticals 2024, 17, 568.
https://doi.org/10.3390/ph17050568
AMA Style
Velidakis N, Stachteas P, Gkougkoudi E, Papadopoulos C, Kadoglou NPE.
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review. Pharmaceuticals. 2024; 17(5):568.
https://doi.org/10.3390/ph17050568
Chicago/Turabian Style
Velidakis, Nikolaos, Panagiotis Stachteas, Evangelia Gkougkoudi, Christodoulos Papadopoulos, and Nikolaos P. E. Kadoglou.
2024. "Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review" Pharmaceuticals 17, no. 5: 568.
https://doi.org/10.3390/ph17050568
APA Style
Velidakis, N., Stachteas, P., Gkougkoudi, E., Papadopoulos, C., & Kadoglou, N. P. E.
(2024). Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review. Pharmaceuticals, 17(5), 568.
https://doi.org/10.3390/ph17050568
